This service will be redeveloped soon — your feedback will help us to improve it.

Investigating the Neuropathology of Obstructive Sleep Apnoea | Recruiting
Investigating the Neuropathology of... | Recruiting
Investigating the Neuropathology of Obstructive Sleep Apnoea
INcOSA

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Obstructive Sleep Apnoea
  • Inflammation
Primary Contact Details
Chih-Cheng Tsai, MSc
0000 02071883430
See all trial contact details
Recruitment Status
Recruiting
Trial source and source ID number
NCT02967536
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
Our multi-disciplinary research group works closely with people who have obstructive sleep apnoea. This is a life-long illness that causes breathing to stop during sleep, which leads to low-oxygen in the blood. Breathing restarts when the airway at the back of the throat reopens, usually during arousal from sleep. In some people the repeated arousals from sleep cause daytime sleepiness. Our research has shown that the low blood oxygen levels affect thinking and feeling, and in some cases we think it damages the brain cells involved with memory, attention, emotions and decision-making.

This study will investigate the relationship between the amount of oxygen in the blood and the loss (if any) of brain cells. Also how the ability to perform complex tasks is affected in patients that suffer from sleep apnoea. The results will show whether the brain damage in patients with sleep apnoea can be reversed with treatment. These findings will guide doctors in the treatment for sleep apnoea and they will cast light onto the process of memory decline with the aim to preserve brain function.
Research Details
  • This is a cross-sectional physiological study, which is anticipated to last for 4 years. In order to study the mechanism of cognitive dysfunction in Obstructive Sleep Apnoea (OSA), patients will start Continuous Positive Airway Pressure (CPAP) treatment following the confirmed diagnosis of sleep apnoea. CPAP is the treatment of choice for patients with moderate to severe OSA who are sleepy during the day. It is also used in patients with mild OSA if they are excessively sleepy or suffer from cardiovascular risk factors. It is recommended by the National Institute for Clinical Excellence (NICE) as a treatment for adults with moderate or severe OSA (Sleep apnoea - continuous positive airway pressure, NICE 2008). In the proposed study the initiation of CPAP will be within the 18 week period set out in the NHS Improvement Plan and Standards for Better Health (Standards for Better Health, DOH 2004). No patient with a diagnosis of OSA will commence treatment with CPAP later than advised by the NICE guidelines of clinical judgement for the best interest of the patient.

    In order to investigate the neuroinflammation process and discrete changes in the brain of patients with OSA, a minimum of 9 patients with mild OSA and 9 patients with severe OSA will be compared to 9 healthy controls following initial sleep (assessment) study. All participants will undergo a dynamic Positron Emission Tomography with Magnetic Resonance Imaging (PET-MR) scan with the TSPO tracer [18F] DPA-714 at the time of enrolment to the study. Each participant will also have an MRI scan and cognitive testing.
Phase
Sorry, this information is not available
Study Design
Sorry, this information is not available
Study Type
Observational
Intervention
Sorry, this information is not available
Intervention Type
See Interventions above
Primary Outcome Measures
    Levels of neuroinflammation, brain morphology and neurophysiology will be measured via MRI, PET-MRI imaging & EEG.; MRI, PET-MRI & EEG data analyses will begin right after the completion of data collection, and the summary of results will be reported as soon as available, expected before the completion date of the study as per IRAS 01/06/2020.; Cognitive performance using the CANTAB battery.; Cognitive performance data analyses will be conducted after the completion of data collection, and the summary of results will be reported along the rest of results in the summary that will be published before 01/06/2020.
Secondary Outcome Measures
    Genetic analysis and linkage to clinical and neuroimaging data will be measured using biological samples (blood or saliva) analysed and stored in the BioResource for Mental and Neurological Health.; Genetic analysis and linkage to clinical and neuroimaging data analyses are expected to continue after the end of the primary study and they will be independently reported by the BioResource for Mental and Neurological Health KCL, within 5 years of study
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Male
Age Range
18 Years - 70 Years
Who Can Participate
Sorry, this information is not available
Number of Participants
27
Participant Inclusion Criteria
    INCLUSION CRITERIA:

    Participants with OSA:

    - Male patients

    - With untreated OSA either mild (AHI≥5/hour and ≤10/hour)

    - or severe (AHI≥30/hour)

    - With excessive sleepiness (ESS≥9)

    - Aged 18-69 years

    Healthy control group:

    - Male participants

    - No history of sleep disorders

    - AHI≤5/hour

    - No current or previous major neurological or psychiatric disease

    - Not currently undertaking neuropharmacological treatment

    - Non-smoker

    - No history of alcohol or recreational drug abuse

    - No major organ failure

    - Not professional drivers or shift workers

    EXCLUSION CRITERIA:

    - Having other sleep disorders, neurological or psychiatric disease

    - Undertaking neuropharmacological treatment

    - Has a history of alcohol or recreational drug abuse, major organ failure

    - Professional drivers or shift workers

    - Unable to have MR scan (e.g. too heavy (>200Kg) or have ferromagnetic implants)

    - [18F]DPA-714 affinity too low

    - Inability to comprehend what is proposed

    - Inability to travel to the research sites
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
London
Trial Contact(s)
Primary Trial Contact
Chih-Cheng Tsai, MSc
0000 02071883430
Other Trial Contacts
Ivana Rosenzweig, MD, PhD
0000 02071883430
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Investigating the Neuropathology of Obstructive Sleep Apnoea
EudraCT Number
Not available for this trial
Funder(s)
  • Guy's and St Thomas' NHS Foundation Trust
Other Study ID Numbers
170912
Sponsor(s)
King's College London
Key Dates

Recruitment Start Date

Nov 2017

Recruitment End Date

Oct 2020

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

17 Aug 2016

Date updated in source

11 Feb 2019